使用受限制的平均存活时间重新评估晚期泌尿腺癌的治疗方法:系统性审查和网络元分析
Shugo Yajima1, Wei Chen2, Kohei Hirose1
1Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
European urology open science
|February 16, 2026
概括
传统的统计方法可能会因为效果延迟而掩盖免疫检查点抑制剂 (ICI) 试验结果. 限制平均存活时间 (RMST) 分析揭示了早期ICI的损害,并量化了益处,支持其在免疫疗法试验中的使用.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验 临床试验
背景情况:
- 免疫检查点抑制剂 (ICI) 可能会延迟治疗效果,可能违反临床试验中的比例危险 (PH) 假设.
- 晚期泌尿腺癌 (UC) 治疗疗效需要强大的统计评估,特别是免疫疗法.
研究的目的:
- 在涉及ICI的第一线高级UC试验中评估PH假设的有效性.
- 为了比较治疗疗效,使用受限平均存活时间 (RMST) 分析,考虑时间依赖的影响.
主要方法:
- 对ICI或抗体-药物合物的2/3期随机对照试验 (2015-2025) 的系统审查和网络元分析 (NMA).
- 从卡普兰-梅尔曲线重建个体患者数据,并使用Schoenfeld余量测试PH假设.
- 基于RMST的NMA在6个月间隔进行,长达36个月.
主要成果:
- 在50%的总生存率和60%的无进展生存率比较中,PH假设被违反.
- 与化疗相比,ICI单一治疗在12个月内显示出早期的损害,被非显著的危险比率掩盖.
- 恩福图马布维多丁加上潘布罗利祖马布在36个月时显示出5.7个月的优异RMST益处.
结论:
- 一半的现代UC试验违反了PH假设,需要对时间依赖效应进行替代分析.
- RMST分析有效量化了早期ICI单疗损害和整体治疗影响.
- 恩福图马布维多丁加上潘布罗利祖马布显示出最大的RMST益处,因此需要进一步验证.
更多相关视频
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Published on: November 22, 2019
8.3K
05:19A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
889
相关概念视频
01:21Cancer Survival Analysis
784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
01:24Kaplan-Meier Approach
634
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
634
01:20Comparing the Survival Analysis of Two or More Groups
621
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
621
01:20Actuarial Approach
325
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
325